JP3524868B2 - ７−［（４’−トリフルオロメチル−ビフェニル−２−カルボニル）アミノ］−キノリン−３−カルボン酸アミド、及びアポリポタンパク質ｂの分泌阻害方法 - Google Patents

７−［（４’−トリフルオロメチル−ビフェニル−２−カルボニル）アミノ］−キノリン−３−カルボン酸アミド、及びアポリポタンパク質ｂの分泌阻害方法

Info

Publication number
JP3524868B2
JP3524868B2 JP2000344267A JP2000344267A JP3524868B2 JP 3524868 B2 JP3524868 B2 JP 3524868B2 JP 2000344267 A JP2000344267 A JP 2000344267A JP 2000344267 A JP2000344267 A JP 2000344267A JP 3524868 B2 JP3524868 B2 JP 3524868B2
Authority
JP
Japan
Prior art keywords
quinoline
carboxylic acid
amino
carbonyl
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000344267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001139555A (ja
Inventor
ピーター・バーティナト
アーネスト・セイイチ・ハマナカ
ロジャー・ベンジャミン・ラッゲリ
ダグラス・ポール・ウィルソン
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2001139555A publication Critical patent/JP2001139555A/ja
Application granted granted Critical
Publication of JP3524868B2 publication Critical patent/JP3524868B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000344267A 1999-11-10 2000-11-10 ７−［（４’−トリフルオロメチル−ビフェニル−２−カルボニル）アミノ］−キノリン−３−カルボン酸アミド、及びアポリポタンパク質ｂの分泌阻害方法 Expired - Fee Related JP3524868B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16480399P 1999-11-10 1999-11-10
US60/164803 1999-11-10
US22495600P 2000-08-11 2000-08-11
US60/224956 2000-08-11

Publications (2)

Publication Number Publication Date
JP2001139555A JP2001139555A (ja) 2001-05-22
JP3524868B2 true JP3524868B2 (ja) 2004-05-10

Family

ID=26860863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000344267A Expired - Fee Related JP3524868B2 (ja) 1999-11-10 2000-11-10 ７−［（４’−トリフルオロメチル−ビフェニル−２−カルボニル）アミノ］−キノリン−３−カルボン酸アミド、及びアポリポタンパク質ｂの分泌阻害方法

Country Status (6)

Country Link
US (2) US6369075B1 (US06369075-20020409-C00011.png)
EP (1) EP1099701A1 (US06369075-20020409-C00011.png)
JP (1) JP3524868B2 (US06369075-20020409-C00011.png)
BR (1) BR0005322A (US06369075-20020409-C00011.png)
CA (1) CA2325358C (US06369075-20020409-C00011.png)
MX (1) MXPA00011105A (US06369075-20020409-C00011.png)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6889385B1 (en) * 2000-01-14 2005-05-03 Terayon Communication Systems, Inc Home network for receiving video-on-demand and other requested programs and services
US20020059637A1 (en) * 2000-01-14 2002-05-16 Rakib Selim Shlomo Home gateway for video and data distribution from various types of headend facilities and including digital video recording functions
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE10033337A1 (de) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2002014276A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
AU2002307839B2 (en) * 2001-06-28 2006-03-16 Zoetis P Llc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
SK2242004A3 (en) * 2001-10-25 2004-11-03 Takeda Chemical Industries Ltd Quinoline compound
EP1465613A2 (de) * 2002-01-10 2004-10-13 Boehringer Ingelheim Pharma GmbH & Co. KG KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
ES2316777T3 (es) * 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
PL372887A1 (en) 2002-02-27 2005-08-08 Pfizer Products Inc. Acc inhibitors
KR100717098B1 (ko) * 2002-02-28 2007-05-10 니뽄 다바코 산교 가부시키가이샤 에스테르 화합물 및 그 의약 용도
US20040186131A1 (en) * 2002-08-30 2004-09-23 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
AU2003262946A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
BR0317426A (pt) * 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicéridos microssomais
BR0317323A (pt) * 2002-12-20 2005-11-16 Pfizer Prod Inc Inibidores de proteìna de transferência de triglicerìdeos microssomal
JP2006519229A (ja) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US7615575B2 (en) 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ES2401645T3 (es) 2003-06-19 2013-04-23 Merck Serono Sa Uso de agentes moduladores de la conversión de priones
CA2533594C (en) * 2003-07-23 2013-04-02 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
EP1650192A4 (en) 2003-07-24 2007-03-21 Astellas Pharma Inc QUINOLONE DERIVATIVE OR SALT THEREOF
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
GB0323348D0 (en) * 2003-10-06 2003-11-05 Cambridge Theranostics Ltd Methods and means for modulating lipid metabolism
BRPI0415167A (pt) * 2003-10-07 2006-11-28 Renovis Inc composto de amina como ligandos de canal de ìon e usos dos mesmos
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
MX2007004973A (es) * 2004-10-25 2007-06-14 Japan Tobacco Inc Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.
CA2588087A1 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
JP2009545579A (ja) 2006-08-01 2009-12-24 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物、及びｐｄｅ４阻害薬としてのその使用
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
US8383852B2 (en) * 2007-02-16 2013-02-26 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
HUE028064T2 (en) 2007-12-03 2016-11-28 Obe Therapy Biotechnology Inhibitors of enteropeptidase boropeptide and their use in the treatment of diseases associated with obesity, overweight and / or abnormal fat metabolism
WO2009119817A1 (ja) 2008-03-28 2009-10-01 武田薬品工業株式会社 安定なヴィナミジニウム塩およびそれを用いた含窒素複素環合成
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
US9309237B2 (en) 2011-09-06 2016-04-12 New York Blood Center, Inc. HIV inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
ES2764440T3 (es) 2014-09-19 2020-06-03 New York Blood Center Inc Fenilpirrolcarboxamidas sustituidas con actividad terapéutica en VIH
GB2589910B (en) * 2019-12-12 2021-12-01 Henkel IP & Holding GmbH Process for preparing cyanoacetates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US5919795A (en) 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904262B1 (en) 1996-01-16 2004-04-21 Bristol-Myers Squibb Company Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919795A (en) 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
CA2325358C (en) 2005-08-02
CA2325358A1 (en) 2001-05-10
JP2001139555A (ja) 2001-05-22
MXPA00011105A (es) 2002-05-23
US6369075B1 (en) 2002-04-09
US20020132806A1 (en) 2002-09-19
US6713489B2 (en) 2004-03-30
EP1099701A1 (en) 2001-05-16
BR0005322A (pt) 2001-07-17

Similar Documents

Publication Publication Date Title
JP3524868B2 (ja) ７−［（４’−トリフルオロメチル−ビフェニル−２−カルボニル）アミノ］−キノリン−３−カルボン酸アミド、及びアポリポタンパク質ｂの分泌阻害方法
US7368573B2 (en) Triamide-substituted heterobicyclic compounds
JP3270764B2 (ja) アポｂ−分泌／ｍｔｐ阻害性アミド
US6821964B2 (en) Modulators of chemokine receptor activity
JP3487591B2 (ja) 肥満症の治療方法及び肥満症の治療に有用な化合物の同定方法
JP5685532B2 (ja) 新しい治療用作用物質
US5670526A (en) 1,3,4-oxadiazoles
US20020006946A1 (en) Tetrazole compounds as thyroid receptor ligands
KR20010098829A (ko) 뉴로텐신 수용체 리간드를 포함하는 비만을 치료하기 위한약학 조성물
KR20050120773A (ko) 멜라노코르틴-4 수용체 작용제로서의 아실화스피로피페리딘 유도체
JP2011530602A (ja) Ｎ−ヘテロ環式ｍ１受容体ポジティブアロステリックモジュレーター
CA3144869C (en) Thieno[3,2-b]thiophene-2-carboxylic acid compounds having bckdk inhibiting activity
JP2005520797A (ja) プロスタグランジン受容体リガンドとしてのキノリノン
TW200831497A (en) Carboxamide compounds and their use
JP2002053564A (ja) 甲状腺受容体リガンド
WO2019046668A1 (en) AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
US20040110951A1 (en) Thyroid receptor ligands
KR20150064245A (ko) 스핑고신 포스페이트 수용체의 신규한 모듈레이터
EP1099442A2 (en) Methods of administering apo B-secretion/MTP inhibitors
JP2006516028A (ja) ミクロソームトリグリセリド輸送タンパク質阻害剤
TWI552750B (zh) 作為ｋｃｎｑ２／３鉀離子通道調節劑之經取代之２－氧基－及2－硫基－二氫喹啉－３－羧醯胺
CN112262129A (zh) 基于三氮杂环十二烷磺酰胺(“tcd”)的蛋白质分泌抑制剂
AU6967400A (en) Methods of administering APO B-secretion/MTP inhibitors
MXPA01000939A (en) Tetrazole compounds as thyroid receptor ligands

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040213

LAPS Cancellation because of no payment of annual fees